Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity: an open-label pilot study.

BMJ Open Gastroenterol · 2021 · PMC8117993 · PMID 33975891

Europe PMC DOI

hedged sentence

0.1760

closest p · 3.5× alpha

0.1760

boldest claim

The sentences

did not reach statistical significancep=0.176not close (p > 0.1)

Following 8 weeks of treatment with sitagliptin, the median reduction from baseline in absolute wet weight output of −174 g/day (−1510, 675) did not reach statistical significance (p=0.176).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.